Adjuvant Treatment in Non-Small Cell Lung Cancer | Zendy

Mustafa Gürbüz | Zendy; Yüksel Ürün | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Treatment in Non-Small Cell Lung Cancer

Author(s) -

Mustafa Gürbüz,

Yüksel Ürün

Publication year - 2018

Publication title -

journal of ankara university faculty of medicine

Language(s) - English

Resource type - Journals

ISSN - 1307-5608

DOI - 10.4274/atfm.66375

Subject(s) - medicine , lung cancer , adjuvant , oncology , immunotherapy , stage (stratigraphy) , disease , chemotherapy , lung , adjuvant chemotherapy , adjuvant therapy , cancer , surgery , breast cancer , paleontology , biology

Lung cancer occurred in approximately 1,8 million patients and caused an estimated 1,6 million deaths in 2012, worldwide. NSCLC constitutes approximately 85% of all lung cancers. Patients with early-stage NSCLC are surgically treated for curative goals. However, many patients are at risk of recurrence despite complete resection. This suggests that a large proportion of patients have the micrometastatic disease even at the early course of the disease. In this review, we aimed to evaluate the results of adjuvant chemotherapy, targeted therapy and immunotherapy studies to improve survival in NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research